Engineered Bacteria Exosome Delivery for Intestinal Herpesvirus Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Human herpesvirus infections are associated with age-related neurodegenerative diseases, but existing treatments are inadequate, often leading to resistance and side effects, and the causal relationship remains unclear.
Innovation Solution
Oral delivery of exosomes containing customized antiviral factors, such as miRNAs and proteins, via engineered bacteria to target and inhibit herpesvirus activity in the intestinal tract, combined with recombinant bacteria to release therapeutic exosomes, addressing intestinal herpesvirus-mediated inflammation and dysbiosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antiviral treatments are used to treat herpesvirus infections, then viral activity is suppressed, but resistance develops and side effects occur
Solution Approach 1:
The patent uses engineered bacteria as intermediaries to deliver exosomes containing antiviral factors to the intestinal tract. These bacteria act as carriers that release therapeutic agents locally, providing sustained antiviral activity while reducing systemic exposure and resistance development. The exosomes serve as another intermediary layer, protecting the antiviral factors and enabling targeted delivery to infected cells.
Solution Approach 2:
The patent extracts and isolates specific antiviral factors (such as miRNAs and proteins) into exosomes, separating the therapeutic components from whole virus particles or crude extracts. This extraction process allows for purified, targeted therapy that addresses specific viral mechanisms while minimizing off-target effects and resistance.
2Object-affected harmful factors
If herpesvirus infections are left untreated, then resistance and side effects are avoided, but intestinal inflammation and neurodegeneration progress
Solution Approach 1:
The patent employs engineered bacteria that are orally administered and establish themselves in the intestinal tract beforehand, creating a ready-to-act therapeutic system. These bacteria continuously monitor and release antiviral exosomes as needed, providing preliminary protection before severe inflammation or neurodegeneration can develop. This preventive approach addresses viral reactivation early in the disease process.
Solution Approach 2:
The engineered bacteria are designed to autonomously detect herpesvirus presence and release appropriate antiviral exosomes without requiring external intervention. The bacteria self-regulate their therapeutic output based on local conditions, providing adaptive, on-demand treatment that responds to viral reactivation events as they occur in the intestinal environment.
3Ease of operation
If oral delivery of exosomes is used to treat intestinal herpesvirus, then targeted therapy is achieved, but delivery complexity increases
Solution Approach 1:
The patent uses engineered bacteria as natural delivery vehicles that simplify the complex task of exosome administration. Instead of requiring sophisticated external delivery devices, the bacteria themselves serve as living carriers that naturally traverse the gastrointestinal tract and release exosomes at the target site. This biological intermediary system converts a complex engineering problem into a more manageable biological solution.
Solution Approach 2:
The patent combines multiple therapeutic functions into a single engineered bacterial system that simultaneously provides antiviral exosome delivery, sustained release capability, and targeted action in the intestinal tract. By merging delivery vehicle, release mechanism, and therapeutic agent into one integrated system, the overall complexity is reduced compared to using separate components for each function.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Prevents intestinal herpesvirus activity, reduces inflammation and microbiota dysbiosis, and potentially treats or delays age-related neurodegenerative diseases like Parkinson's and Alzheimer's by enhancing intestinal barrier function and immune response.
Implementation Method 1
Oral delivery of exosomes containing customized antiviral factors, such as miRNAs and proteins
Implementation Method 2
ingestion of recombinant bacteria engineered to release therapeutic factors in exosomes
Data Source
AI summary
Human herpesviruses can infect barrier and immune cells of the intestines to cause microbiome dysbiosis and inflammation. Microbiome dysbiosis can affect the brain function, and inflammation can compromise the intestinal barrier and lead to microbial translocation. Embodiments may restrict herpesvirus activity and injury by 1) the oral administration of exosomes containing factors to inhibit viral activity and restore homeostasis, and 2) the oral administration of recombinant bacteria that produce exosomes containing factors to inhibit viral activity and restore homeostasis. Embodiments also measure HHV activity in stool by ELISA immunoassay of HHV proteins.